Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
NCT ID: NCT06439576
Last Updated: 2025-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
1000 participants
OBSERVATIONAL
2024-05-09
2027-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients
NCT06572553
Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration
NCT07088445
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
NCT05569148
A Study of EXG102-031 in Participants With wAMD
NCT06183814
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: Patients with nAMD
Faricimab
The dosing and treatment duration of the studied medicinal product is at the discretion of the physician in accordance with clinical practice and labeling in China.
Cohort 2: Patients with DME
Faricimab
The dosing and treatment duration of the studied medicinal product is at the discretion of the physician in accordance with clinical practice and labeling in China.
Cohort 3: Patients with RVO
Faricimab
The dosing and treatment duration of the studied medicinal product is at the discretion of the physician in accordance with clinical practice and labeling in China.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Faricimab
The dosing and treatment duration of the studied medicinal product is at the discretion of the physician in accordance with clinical practice and labeling in China.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Female and male Chinese patients, who had been diagnosed with nAMD, DME, or RVO by CFP, OCT, FFA, ICGA, or OCTA
3. ≥50 years old for patients with nAMD, ≥18 years old both for patients with DME and RVO, at the time of signing informed consent (or the first administration of faricimab, whichever occurs first)
4. Patients for whom the decision to receive treatment with faricimab is made prior to and independent from study participation
5. Patients have received at least one faricimab treatment (the first dose) in the study eye
Exclusion Criteria
2. Active ocular inflammation or suspected / active ocular infection in either eye
3. Received any other anti-VEGF treatment after faricimab
4. Received any steroid treatment within 6 months (180 days) before the first faricimab treatment in the study eye
5. Any participation in any other clinical trials currently
6. Patients could not provide the clinical data (visual acuity and OCT images) within 2 weeks (14 days) before receiving the initial faricimab injection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Roche Pharmaceutical Co., Ltd
UNKNOWN
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Joint Shantou International Eye Center
Shantou, Guangdong, China
The First Affiliated Hospital of Henan UN of Science and Technology
Luoyang, Henan, China
Taihe Hospital of Shiyan
Shiyan, Hubei, China
Xuzhou No.1 Peoples Hospital
Xuzhou, Jiangsu, China
Fushun Eye Hospital
Fushun, Liaoning, China
Panjin Central Hospital
Panjin, Liaoning, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
Affiliated Hospital of Shandong Second Medical University
Weifang, Shandong, China
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
The First People's Hospital of Chengdu
Chengdu, Sichuan, China
The First People's Hospital of Kashgar
Kashgar, Xinjiang Uygur, China
The First People's Hospital of Yunnan Province
Kunming, Yun'nan, China
Jinhua municipal central hospital
Jinhua, Zhejiang, China
Peking University People's Hospital
Beijing, , China
Sichuan Provincial People's Hospital
Chengdu, , China
People's Hospital of Dingzhou
Dingzhou, , China
Dongyang People's Hospital
Dongyang, , China
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, , China
Guizhou Provincial People's Hospital
Guiyang, , China
Eye Hospital of Shandong First Medical University
Jinan, , China
The First Affiliated Hospital of Lanzhou University
Lanzhou, , China
The Affiliated Hospital of Southwest Medical University, Zhongshan Campus
Luzhou, , China
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
Nanjing, , China
The People?s Hospital of Guangxi Zhuang Autonomous Region
Nanning, , China
Qingdao Eye Hospital of Shandong First Medical University
Qingdao, , China
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, , China
Shanghai Tenth People's Hospital
Shanghai, , China
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, , China
Shanghai Zhoupu Hospital
Shanghai, , China
Shenyang Fourth People's Hospital
Shenyang, , China
Shenzhen Eye Hospital
Shenzhen, , China
Hebei People's Hospital
Shijiazhuang, , China
Shanxi Bethune Hospital
Taiyuan, , China
Tianjin Eye Hospital
Tianjin, , China
Eye Hospital, Wenzhou Medical University
Wenzhou, , China
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
Wuhan, , China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, , China
Xiamen Eye Center Of Xiamen University
Xiamen, , China
Hebei Eye Hospital
Xingtai, , China
Henan Provincial Eye Hosptial
Zhengzhou, , China
Affiliated Hospital of Zunyi Medical University
Zunyi, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML45401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.